XNW29016

targets PARG via inhibition

Investigated by: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Evopoint Biosciences Inc.

today NCT06987500 · Ph 1/2

20262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT06987500	Apr 2025 → Feb 2027 expected	—	Evopoint Biosciences Inc.	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	XNW29016	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06987500 ↗
Action	Inhibit	“PARG Inhibitor” NCT06987500 ↗
Route	Oral	“Oral Medication” NCT06987500 ↗
Target	PARG	“PARG Inhibitor XNW29016” NCT06987500 ↗